Alpha-7 Nicotinic Receptor-Targeted Cinobufagin Induces Antinociception and Inhibits NF-κB Signaling Pathway in DRG...

Area of Science:

• Pharmacology
• Neuroscience
• Pain Research

Background:

• Cinobufagin (CBG) exhibits known antinociceptive properties.
• The precise mechanism and molecular targets underlying CBG's pain-relieving effects remain largely undetermined.

Purpose of the Study:

• To investigate the antinociceptive effect of Cinobufagin (CBG) in thermal and chemical pain models.
• To elucidate the molecular target and signaling pathway involved in CBG-mediated analgesia.

Main Methods:

• Utilized hot-plate, formalin, and acetic acid writhing tests in mice to assess antinociception.
• Employed alpha-7 nicotinic receptor antagonists (methyllycaconitine citrate and siRNA) to block CBG's effects.
• Investigated co-expression of alpha-7 nicotinic receptor and IκB/NF-κB in DRG neurons via immunofluorescence.
• Analyzed p-IκB and p-NF-κB formation and inflammatory cytokine expression using Western blot and ELISA.

Main Results:

• CBG produced a dose-dependent antinociceptive effect in all pain models.
• The antinociceptive activity of CBG was significantly blocked by alpha-7 nicotinic receptor antagonists.
• CBG modulated the NF-κB signaling pathway and inflammatory cytokine expression in dorsal root ganglion (DRG) neurons, dependent on alpha-7 nicotinic receptor activation.

Conclusions:

• Cinobufagin (CBG) exerts its antinociceptive effects by activating alpha-7 nicotinic receptors.
• Activation of alpha-7 nicotinic receptors by CBG leads to the inhibition of the NF-κB signaling pathway in DRG neurons.
• This pathway modulation by CBG ultimately results in significant pain relief in mice.